Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripasudil for Cornea Clearing After DMEK in Fuchs' Dystrophy
NCT03813056Phase 2Recruiting
- Start
- Mar 2019
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Fuchs endothelial dystrophy (FED) comparing Glanatec with Placebo (2 arms). Primary endpoint: Time to corneal clearance at 6 months. Started Mar 2019; status: recruiting.
02
Drugs
ripasudil
03
Conditions
Fuchs endothelial dystrophy (FED)
Beyond the preview
Go deeper on NCT03813056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03813056.